Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicenter, Controlled, Adaptive II/III Study to Compare Neoadjuvant Chemotherapy of Docetaxel, Oxaliplatin, S-1(DOS) Combined With Toripalimab Versus Oxaliplatin, S-1(SOX) Combined With Toripalimab in Locally Advanced Gastric Adenocarcinoma (RESOLVE-2 Study)

NCT03691454 is registered in ClinicalTrials.gov with Peking University as lead sponsor.

NCT NCT03691454
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03691454 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicenter, Controlled, Adaptive II/III Study to Compare Neoadjuvant Chemotherapy of Docetaxel, Oxaliplatin, S-1(DOS) Combined With Toripalimab Versus Oxaliplatin, S-1(SOX) Combined With Toripalimab in Locally Advanced Gastric Adenocarcinoma (RESOLVE-2 Study)
Lead sponsor
Peking University
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
June 28, 2018
Completion date
June 30, 2027
Enrollment
248 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric adenocarcinoma